Through week 12, the placebo-controlled portion of the study, the percentages of study participants who experienced at least one adverse event (AE) were comparable between the placebo group (49 percent) and the ustekinumab 45 mg group (53 percent) and 90 mg group (48 percent). Discontinuation due to an AE occurred in 0.2 percent and one percent of patients in the respective ustekinumab groups, compared with two percent of patients in the placebo group. Two percent and one percent of patients receiving 45 mg or 90 mg ustekinumab, respectively, experienced at least one serious AE compared with two percent of patients receiving placebo.
'/>"/>
| Contact: Michael Parks 215-325-4010 Centocor, Inc. Source:Eurekalert |